Opus Genetics completes Phase 3 enrollment for AAV gene therapy OPGx-LCA5

Opus Genetics announced that the last patient has been enrolled in its registrational phase 3 clinical trial evaluating OPGx-LCA5, the company's investigational gene therapy for LCA5-associated inherited retinal disease (IRD).¹ Completion of enrollment follows the program's acceptance into the FDA’s Rare Disease Evidence Principles (RDEP) program in May 2026, and the phase 3 study was designed in collaboration with the FDA to support a potential Biologics License Application (BLA) for what could become the first approved therapy for patients with LCA5-associated IRD.¹

How does OPGx-LCA5 work?

OPGx-LCA5 uses an adeno-associated virus 8 (AAV8) vector to deliver a functional copy of the LCA5 gene to the outer retina.¹ The therapy addresses a form of Leber congenital amaurosis caused by biallelic mutations in LCA5, which encodes the lebercilin protein; the resulting disease is an early-onset, severe inherited retinal dystrophy for which there are currently no approved treatments.¹ The registrational trial is evaluating a one-time subretinal administration of OPGx-LCA5 and incorporates a six-month run-in period, in which patients serve as their own baseline comparators before treatment, an evidence-generation approach the company designed in consultation with the FDA to suit an ultra-rare disease population where a conventional placebo-controlled design would be difficult to enroll.¹

Why is this trial design significant for an ultra-rare disease?

LCA5-associated IRD affects a very small global patient population. LCA5 accounts for only an estimated 1% to 2% of all Leber congenital amaurosis cases, a disease group with an overall prevalence of roughly 1 in 30,000 to 1 in 81,000 births that is responsible for about 20% of childhood blindness.² Because a traditional large randomized trial isn't feasible in a population this small, Opus Genetics worked with the FDA through the RDEP program, which is designed to provide guidance on the types of evidence that can support substantial evidence of effectiveness, including the potential use of a single adequate and well-controlled study supported by confirmatory evidence.¹ OPGx-LCA5 has received Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA in recognition of that unmet need, and the Rare Pediatric Disease designation carries potential eligibility for a Priority Review Voucher upon approval, an incentive the company has previously highlighted as part of its development strategy.¹ Opus Genetics has said it may be able to submit a BLA based on six-month efficacy data, with 12-month durability data supplied to the FDA during the review period.¹

What did company leadership

say?

George Magrath, M.D., chief executive officer of Opus Genetics, said, "Achieving full enrollment in our registrational phase 3 trial is a significant milestone for the OPGx-LCA5 program and reflects the dedication of participating patients and families, our clinical investigators, and our team. With enrollment now complete, we remain on track to initiate dosing in the fourth quarter of 2026, report topline data by the end of 2027, and continue advancing OPGx-LCA5 to bring the first potential treatment to patients with LCA5-associated inherited retinal disease."¹

What happens next?

Opus Genetics expects to begin dosing patients in the phase 3 trial during the fourth quarter of 2026, with topline six-month efficacy data anticipated by the end of 2027.¹ If the trial meets its primary endpoint, the company may pursue a BLA submission based on that six-month data, with 12-month durability data provided to the FDA during the review process.¹ OPGx-LCA5 is the lead candidate in a broader Opus Genetics pipeline that includes seven AAV-based gene therapy programs for inherited retinal diseases, including a second clinical-stage candidate, OPGx-BEST1, targeting BEST1-related retinal degeneration.¹ A successful outcome for OPGx-LCA5 would mark the company's first potential product approval and could serve as a proof of concept for the rest of its inherited retinal disease portfolio.

References

1. Opus Genetics completes patient enrollment in registrational Phase 3 trial of OPGx-LCA5 for LCA5-associated inherited retinal disease. Press release. Opus Genetics, Inc; August 3, 2026. Accessed August 3, 2026. https://www.globenewswire.com/news-release/2026/08/03/3337367/0/en/Opus-Genetics-Completes-Patient-Enrollment-in-Registrational-Phase-3-Trial-of-OPGx-LCA5-for-LCA5-Associated-Inherited-Retinal-Disease.html
2. Huang CH, Yang CM, Yang CH, Hou YC, Chen TC. Leber's congenital amaurosis: current concepts of genotype-phenotype correlations. Genes (Basel). 2021;12(8):1261. doi:10.3390/genes12081261